Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nls Pharmaceutics Ltd
(NQ:
NLSP
)
4.250
-0.850 (-16.67%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nls Pharmaceutics Ltd
< Previous
1
2
3
4
5
6
7
Next >
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
September 08, 2022
Via
ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
September 06, 2022
Upgrades
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 06, 2022
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
Via
InvestorPlace
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
March 16, 2022
Via
Benzinga
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
August 24, 2022
Gainers
Via
Benzinga
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Why Windtree Therapeutics Is Trading Higher By Over 60%, Here Are 61 Stocks Moving In Tuesday's Mid-Day Session
August 23, 2022
Gainers
Via
Benzinga
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
Via
ACCESSWIRE
Stocks That Hit 52-Week Lows On Monday
July 25, 2022
On Monday, 100 companies reached new 52-week lows.
Via
Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
July 25, 2022
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 22, 2022
Good morning! We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday!
Via
InvestorPlace
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session
July 22, 2022
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Via
Benzinga
Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket
July 22, 2022
Gainers
Via
Benzinga
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
July 22, 2022
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period...
Via
Benzinga
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
June 10, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
June 06, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Bankruptcy
Initial Public Offering
Exposures
Financial
Legal
Securities Market
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
June 02, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
April 26, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 13, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
April 01, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
March 31, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
March 28, 2022
- Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
March 25, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
March 16, 2022
- Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial - Safety and...
From
NLS Pharmaceutics AG
Via
AccessWire
80 Biggest Movers From Yesterday
March 17, 2022
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-...
Via
Benzinga
NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
February 25, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.